A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

Retrovirology

Volumn 9, Issue , 2012, Pages

  Lu, Lu ^a,b   Pan, Chungen ^b,c   Li, Yuan ^a,b   Lu, Hong ^b   He, Wu ^b   Jiang, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

gp41; HIV 1; HIV 1 fusion inhibitor; Inactivation; Peptide; Six helix bundle

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 41; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN 2DLT; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; ARTICLE; BINDING SITE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET CELL; VIRION; VIRUS ENTRY; VIRUS INACTIVATION;

AMINO ACID SEQUENCE; ANTIGENS, CD4; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; VIRION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870562697     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-104     Document Type: Article

References (60)

1. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N Engl J Med 2003, 348:2175-2185. 10.1056/NEJMoa035026, 12637625.
2. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732. 10.1128/AAC.49.11.4721-4732.2005, 1280117, 16251317.
3. Polsky B, Baron PA, Gold JW, Smith JL, Jensen RH, Armstrong D. In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet 1988, 1:1456.
4. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000, 62:149-154. 10.1016/S0010-7824(00)00156-6, 11124363.
5. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998, 93:681-684. 10.1016/S0092-8674(00)81430-0, 9630213.
6. Jiang S, Debnath AK. Development of HIV entry inhibitors taregeted to the coiled coil regions of gp41. Biochem Biophys Res Commun 2000, 269:641-646. 10.1006/bbrc.1999.1972, 10720469.
7. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008, 5:111. 10.1186/1742-4690-5-111, 2633019, 19077194.
8. Bhakta SJ, Shang L, Prince JL, Claiborne DT, Hunter E. Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology 2011, 8:37. 10.1186/1742-4690-8-37, 3117779, 21569545.
9. Dimonte S, Mercurio F, Svicher V, D'Arrigo R, Perno CF, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 2011, 8:33. 10.1186/1742-4690-8-33, 3117778, 21569409.
10. D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000, 284:215-222. 10.1001/jama.284.2.215, 10889596.
11. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317:1930-1934. 10.1126/science.1145373, 2278242, 17901336.
12. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 1990, 87:6574-6578. 10.1073/pnas.87.17.6574, 54579, 2395859.
13. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990, 112:247-253.
14. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, Gee-Estrada K, Mefford M, Gabuzda D, Smith AB, Sodroski J. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 2009, 5:e1000360. 10.1371/journal.ppat.1000360, 2655723, 19343205.
15. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993, 365:113.
16. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91:9770-9774. 10.1073/pnas.91.21.9770, 44898, 7937889.
17. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995, 2:1075-1082. 10.1038/nsb1295-1075, 8846219.
18. Lu M, Kim PS. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997, 15:465-471. 10.1080/07391102.1997.10508958, 9439994.
19. Delmedico M, Bray B, Cammack N, Davison D, Dwyer J, Frick L, Tvermoes N, Wring S, Zhang H, Greenberg M. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections 2006, Abstract No. 48.
20. Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007, 104:12772-12777. 10.1073/pnas.0701478104, 1937542, 17640899.
21. Liu Y, Zhao TJ, Yan YB, Zhou HM. Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system. Protein Expr Purif 2005, 44:155-161. 10.1016/j.pep.2005.03.030, 15882951.
22. Lu L, Zhu Y, Diao J, Wang Z, Chen YH. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. Vaccine 2008, 26:845-852. 10.1016/j.vaccine.2007.11.022, 18191003.
23. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009, 4:495-505. 10.1038/nprot.2009.22, 19300443.
24. Ibegbu CC, Kennedy MS, Maddon PJ, Deen KC, Hicks D, Sweet RW, McDougal JS. Structural features of CD4 required for binding to HIV. J Immunol 1989, 142:2250-2256.
25. Neurath AR, Strick N, Li YY. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis 2002, 2:27. 10.1186/1471-2334-2-27, 139971, 12445331.
26. Neurath AR, Strick N, Jiang S, Li YY, Debnath AK. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of " dead-end" gp41 six-helix bundles. BMC Infect Dis 2002, 2:6. 10.1186/1471-2334-2-6, 113252, 11983022.
27. Liu S, Lu H, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005, 280:11259-11273. 10.1074/jbc.M411141200, 15640162.
28. Liu S, Zhao Q, Jiang S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 2003, 24:1303-1313.
29. Li L, He L, Tan S, Guo X, Lu H, Qi Z, Pan C, An X, Jiang S, Liu S. 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother 2010, 54:1700-1711. 10.1128/AAC.01046-09, 2863607, 20194691.
30. Sullivan N, Sun Y, Binley J, Lee J, Barbas CF, Parren PW, Burton DR, Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998, 72:6332-6338. 109776, 9658072.
31. Chertova E, Bess JJ, Crise BJ, Sowder RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002, 76:5315-5325. 10.1128/JVI.76.11.5315-5325.2002, 137021, 11991960.
32. McDougal JS, Kennedy MS, Orloff SL, Nicholson JK, Spira TJ. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol 1996, 70:5236-5245. 190480, 8764033.
33. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995, 11:533-539. 10.1089/aid.1995.11.533, 7576908.
34. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004, 48:423-429. 10.1128/AAC.48.2.423-429.2004, 321533, 14742190.
35. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003, 77:2859-2865. 10.1128/JVI.77.5.2859-2865.2003, 149752, 12584309.
36. Balzarini J, Velazquez S, San-Felix A, Karlsson A, Perez-Perez MJ, Camarasa MJ, De CE. Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues. Mol Pharmacol 1993, 43:109-114.
37. Feldblum PJ, Weir SS, Cates W. The protective effect of condoms and nonoxynol-9 against HIV infection: a response to Wittkowski and colleagues. Am J Public Health 1999, 89:108-110. 1508499, 9987480.
38. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008, 3:e1474. 10.1371/journal.pone.0001474, 2190795, 18213382.
39. Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res 1999, 43:157-173. 10.1016/S0166-3542(99)00044-3, 10551374.
40. Catalone BJ, Miller SR, Ferguson ML, Malamud D, Kish-Catalone T, Thakkar NJ, Krebs FC, Howett MK, Wigdahl B. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother 2005, 59:430-437. 10.1016/j.biopha.2005.07.008, 16154721.
41. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006, 6:90. 10.1186/1471-2334-6-90, 1523343, 16740164.
42. Schenten D, Marcon L, Karlsson GB, Parolin C, Kodama T, Gerard N, Sodroski J. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol 1999, 73:5373-5380. 112593, 10364284.
43. Clapham PR, McKnight A, Weiss RA. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol 1992, 66:3531-3537. 241134, 1583722.
44. Allan JS, Strauss J, Buck DW. Enhancement of SIV infection with soluble receptor molecules. Science 1990, 247:1084-1088. 10.1126/science.2309120, 2309120.
45. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992, 66:235-243. 238280, 1727487.
46. Bouma P, Leavitt M, Zhang PF, Sidorov IA, Dimitrov DS, Quinnan GV. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1. J Virol 2003, 77:8061-8071. 10.1128/JVI.77.14.8061-8071.2003, 161940, 12829845.
47. Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol 2011, 85:10785-10797. 10.1128/JVI.05331-11, 3187517, 21835789.
48. Papanikolopoulou K, Forge V, Goeltz P, Mitraki A. Formation of Highly Stable Chimeric Trimers by Fusion of an Adenovirus Fiber Shaft Fragment with the Foldon Domain of Bacteriophage T4 Fibritin. J Biol Chem 2004, 279:8991-8998. 10.1074/jbc.M311791200, 14699113.
49. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 1998, 72:10213-10217. 110570, 9811763.
50. Huang JH, Liu ZQ, Liu S, Jiang S, Chen YH. Identification of the HIV-1 gp41 core-binding motif - HXXNPF. FEBS Lett 2006, 580:4807-4814. 10.1016/j.febslet.2006.07.067, 16904109.
51. Zhu Y, Lu L, Xu L, Yang H, Jiang S, Chen YH. Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. J Virol 2010, 84:9359-9368. 10.1128/JVI.00644-10, 2937606, 20592080.
52. Lu L, Zhu Y, Huang J, Chen X, Yang H, Jiang S, Chen YH. Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process: INTERACTION WITH gp41 FUSION CORE. J Biol Chem 2008, 283:16723-16731. 10.1074/jbc.M801083200, 2423246, 18408000.
53. Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 2004, 48:4349-4359. 10.1128/AAC.48.11.4349-4359.2004, 525433, 15504864.
54. Lu H, Zhao Q, Wallace G, Liu S, He Y, Shattock R, Neurath AR, Jiang BS. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses 2006, 22:411-418. 10.1089/aid.2006.22.411, 2788998, 16706617.
55. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72:986-993. 124569, 9444991.
56. Neurath AR, Strick N, Li YY, Debnath AK. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001, 1:17. 10.1186/1471-2334-1-17, 57811, 11602021.
57. Bilello J, Belay S, Weislow O. Development of novel approaches to the evaluation of virucidal agents: separation of treated virions from test compounds. AIDS 2001, 15(Suppl. 1):S39.
58. Li L, Qiao P, Yang J, Lu L, Tan S, Lu H, Zhang X, Chen X, Wu S, Jiang S, Liu S. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology 2010, 7:37. 10.1186/1742-4690-7-37, 2888735, 20420669.
59. Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Biochim Biophys Acta 2012, 1818:2950-2957. 10.1016/j.bbamem.2012.07.020, 22867851.
60. Yu X, Lu L, Cai L, Tong P, Tan S, Zou P, Meng F, Chen YH, Jiang S. Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol 2012, 86:589-593. 10.1128/JVI.05066-11, 3255876, 22013063.